Disc Medicine is a clinical-stage biopharmaceutical company developing therapies for serious hematologic diseases. Its pipeline focuses on modulating heme biosynthesis and iron homeostasis, including programs for rare disorders such as erythropoietic porphyrias and anemias linked to iron dysregulation. The company has essentially no product revenue while advancing candidates through clinical development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -55.3 | — |
| Q3 2025 | 0 | — | -62.3 | — |
| Q4 2025 | 0 | — | -60.5 | — |
| Q1 2026 | 0 | — | -63.5 | — |
| Q2 2026 | 0 | — | -59.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: BitVentures Limited (BVC), nCino, Inc. (NCNO), NeoGenomics, Inc. (NEO), Enterprise Financial Services Corp (EFSC), Addus HomeCare Corporation (ADUS), Vertex, Inc. (VERX)